Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Preeclampsia
Interventions
DEVICE

Apheresis using Liposorber LA-15 System

The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.

Trial Locations (3)

50923

University Hospital of Cologne (Universitat zu Koln), Cologne

02116

Massachusetts General Hospital, Boston

Unknown

University Hospital Leipzig, Leipzig

All Listed Sponsors
collaborator

Kaneka Medical America LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01404910 - Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery | Biotech Hunter | Biotech Hunter